Who are the top shareholders of the Vivo Bio Tech?

The top shareholders of Vivo Bio Tech are Cryptologic Systems Private Limited with 7.5% and Elite Class Asset Holdings Ltd with 7.25%. Individual investors hold a combined 35.48%, and there are no mutual funds or foreign institutional investors involved.

The top shareholders of Vivo Bio Tech include Cryptologic Systems Private Limited, which holds the highest promoter stake at 7.5%. Following closely is Elite Class Asset Holdings Ltd, the highest public shareholder, with a holding of 7.25%. Additionally, individual investors collectively hold 35.48% of the company's shares. There are no mutual funds or foreign institutional investors currently holding shares in the company.

how big is Vivo Bio Tech?

As of Jun 06, Vivo Bio Tech Ltd. has a market capitalization of 67.90 Cr, classifying it as a Micro Cap company, with recent net sales of 46.67 Cr and net profit of 7.28 Cr over the latest four quarters.

Market Cap: <BR>As of Jun 06, Vivo Bio Tech Ltd. has a market capitalization of 67.90 Cr, which classifies it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: <BR>For the latest four quarters, the sum of Net Sales is 46.67 Cr, and the sum of Net Profit is 7.28 Cr. This data is presented on a Consolidated basis.<BR><BR>Balance Sheet Snapshot: <BR>This is Consolidated data for the latest annual period ending Mar'24. Shareholder's Funds are reported at 54.40 Cr, while Total Assets amount to 137.13 Cr.

When is the next results date for Vivo Bio Tech?

No Upcoming Board Meetings

What does Vivo Bio Tech do?

Vivo Bio Tech Ltd. is a full-service Contract Research Organization (CRO) that offers drug development and discovery services to global pharmaceutical and biotech companies. As of March 2025, it reported net sales of 12 Cr and a net profit of 1 Cr, with a market cap of Rs 68 Cr.

Overview: <BR>Vivo Bio Tech Ltd. is a full-service Contract Research Organization (CRO) that provides drug development and discovery services to pharmaceutical and biotech companies worldwide, operating within the Pharmaceuticals & Biotechnology industry and classified as a Micro Cap.<BR><BR>History: <BR>Vivo Bio Tech Limited was established in February 1987. The latest quarterly results reported are for March 2025, showing net sales and profit figures.<BR><BR>Financial Snapshot: <BR>Net Sales: 12 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: 1 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: Rs 68 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 9.00 <BR>Industry P/E: 35 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.68 <BR>Return on Equity: 9.35% <BR>Price to Book: 0.87 <BR><BR>Contact Details: <BR>Address: Survey #349/A Pregnapur Vlge, Gajel Telangana: 502311 <BR>Email: investors@vivobio.com <BR>Website: http://www.vivobio.com

Has Vivo Bio Tech declared dividend?

No Dividend History Available

Who are the peers of the Vivo Bio Tech?

Vivo Bio Tech's peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Roopa Industries, Medi Caps, Dipna Pharmachem, Sandu Pharma, and JFL Life. Vivo Bio Tech has average management risk, below average growth, and a 1-year return of -5.81%, significantly lower than its peers.

Peers: The peers of Vivo Bio Tech are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Roopa Industries, Medi Caps, Dipna Pharmachem, Sandu Pharma, and JFL Life.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, and Dr Reddy's Labs, while Average management risk is found at Vivo Bio Tech, Medi Caps, and JFL Life. Below Average management risk is noted at Roopa Industries and Sandu Pharma, and the rest have varying ratings. Growth is Excellent for Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Below Average growth is seen at Vivo Bio Tech, Divi's Lab., Torrent Pharma, Medi Caps, and Sandu Pharma. Good growth is observed at Roopa Industries and JFL Life, and the rest have varying ratings. Capital Structure is Excellent for Sun Pharma.Inds., Divi's Lab., Cipla, and Dr Reddy's Labs, while Below Average capital structure is noted at Vivo Bio Tech, Roopa Industries, and Sandu Pharma, and the rest have varying ratings.<BR><BR>Return Snapshot: Divi's Lab. has the highest 1-year return at 51.69%, while Vivo Bio Tech has the lowest at -5.81%. Vivo Bio Tech's return is significantly lower than the highest peer. Additionally, the six-month return is negative for Torrent Pharma, Medi Caps, and Sandu Pharma.

Is Vivo Bio Tech overvalued or undervalued?

As of May 26, 2025, Vivo Bio Tech is considered very attractive and undervalued with a PE ratio of 9.33, an EV to EBITDA ratio of 5.88, and a PEG ratio of 0.07, significantly lower than its peers like Sun Pharma and Divi's Lab, despite underperforming the Sensex over the past year.

As of 26 May 2025, the valuation grade for Vivo Bio Tech has moved from attractive to very attractive, indicating a positive shift in its perceived value. The company is currently considered undervalued, with a PE ratio of 9.33, an EV to EBITDA ratio of 5.88, and a PEG ratio of 0.07, all of which suggest that the stock is trading at a significant discount compared to its earnings growth potential.<BR><BR>In comparison to its peers, Vivo Bio Tech stands out with a much lower PE ratio than Sun Pharma (35.25) and Divi's Lab (79.33), both of which are categorized as expensive. Additionally, its EV to EBITDA ratio is significantly better than those of its peers, reinforcing the undervaluation narrative. While Vivo Bio Tech has underperformed the Sensex over the past year with a return of -5.27% compared to the Sensex's 7.60%, its strong valuation metrics suggest that it may present a compelling investment opportunity moving forward.

What is the technical trend for Vivo Bio Tech?

As of May 12, 2025, the trend is mildly bearish due to daily moving averages and monthly bearish indicators, despite some mildly bullish signals on the weekly charts, with the stock underperforming against the Sensex over the past few years.

As of 12 May 2025, the technical trend has changed from bearish to mildly bearish. The current stance is mildly bearish, driven primarily by the daily moving averages indicating a mildly bearish trend, while the monthly MACD and RSI are both bearish. The weekly MACD and KST show mildly bullish signals, but the overall sentiment remains cautious due to the bearish indicators on the monthly Bollinger Bands and the lack of a clear trend in Dow Theory. The stock has underperformed against the Sensex over the past year and three years, further supporting the bearish outlook.

Who are in the management team of Vivo Bio Tech?

As of March 2022, the management team of Vivo Bio Tech includes Kalyan Ram Mangipudi, Alangudi Sankaranarayanan, K Sunder, Hariharan Ravindran, Kunda Kalpana, Karopadi Shivanand Nayak, K Sri Kalyan, and Shyam Sunder Tipparaju, each holding various leadership roles.

As of March 2022, the management team of Vivo Bio Tech includes the following individuals:<BR><BR>1. Kalyan Ram Mangipudi - Whole-time Director<BR>2. Alangudi Sankaranarayanan - Whole-time Director<BR>3. K Sunder - Chairman & Independent Director<BR>4. Hariharan Ravindran - Independent Director<BR>5. Kunda Kalpana - Independent Director<BR>6. Karopadi Shivanand Nayak - Director<BR>7. K Sri Kalyan - Whole Time Director & CFO<BR>8. Shyam Sunder Tipparaju - Additional Director<BR><BR>These members play various roles within the company's leadership structure.

Are Vivo Bio Tech latest results good or bad?

Vivo Bio Tech's latest results are positive, with a 163.74% year-on-year growth in Profit After Tax and record net sales of Rs 12.51 crore. However, a decline in cash reserves raises some liquidity concerns, so while the overall performance is strong, caution is advised regarding cash flow.

Vivo Bio Tech's latest results indicate a positive performance overall. For the quarter ending June 2025, the company reported a Profit After Tax (PAT) of Rs 2.40 crore, which represents an impressive year-on-year growth of 163.74%. Additionally, net sales reached a record high of Rs 12.51 crore, showing consistent growth over the last five quarters.<BR><BR>The financial score has also improved significantly, reflecting a stronger performance compared to previous periods. The operating profit to interest ratio has enhanced to 3.65 times, indicating better management of interest payments.<BR><BR>However, there are some concerns regarding liquidity, as cash and cash equivalents have decreased to Rs 1.28 crore, the lowest in the last three years. The debt-equity ratio stands at 0.69 times, suggesting a reduction in borrowing relative to equity capital, which could be seen as a positive aspect in terms of financial stability.<BR><BR>In summary, while Vivo Bio Tech has shown strong growth in profits and sales, the decline in cash reserves is a point to watch. Overall, the results can be considered good, but with some caution regarding liquidity.

How has been the historical performance of Vivo Bio Tech?

Vivo Bio Tech has experienced fluctuating net sales, declining from INR 55.83 crore in March 2019 to INR 46.67 crore in March 2025, but profitability improved significantly, with profit after tax rising to INR 7.28 crore in March 2025. Despite operational challenges, the company has shown an ability to increase operating profit and total assets during this period.

Answer:<BR>The historical performance of Vivo Bio Tech shows a fluctuating trend in net sales and profitability over the years, with a notable increase in profit after tax in the latest fiscal year.<BR><BR>Breakdown:<BR>Vivo Bio Tech's net sales have shown a decline from INR 55.83 crore in March 2019 to INR 46.67 crore in March 2025, with a slight increase from INR 45.45 crore in March 2024. The total operating income followed a similar trend, peaking at INR 52.23 crore in March 2023 before dropping to INR 46.67 crore in March 2025. The total expenditure, excluding depreciation, decreased from INR 42.88 crore in March 2020 to INR 26.16 crore in March 2025, contributing to an increase in operating profit, which rose from INR 12.47 crore in March 2020 to INR 25.31 crore in March 2025. Profit before tax also saw a significant rise, reaching INR 8.79 crore in March 2025, up from INR 4.06 crore in March 2024. Consequently, profit after tax surged to INR 7.28 crore in March 2025, compared to INR 2.53 crore in March 2024. The company's total assets increased from INR 62.14 crore in March 2020 to INR 143.23 crore in March 2025, while total liabilities also rose from INR 62.14 crore to INR 46.29 crore during the same period. Cash flow from operating activities decreased to INR 11 crore in March 2025, down from INR 15 crore in March 2024, while cash flow from investing activities turned negative at INR -15 crore. Overall, Vivo Bio Tech has demonstrated a capacity for profitability despite fluctuations in sales and operational challenges.

Should I buy, sell or hold Vivo Bio Tech?

Which are the latest news on Vivo Bio Tech?

Why is Vivo Bio Tech falling/rising?

As of 03-Dec, Vivo Bio Tech Ltd. is facing a decline in stock price, currently at Rs 30.27, reflecting a total decline of -1.69% over the past two days and significant underperformance compared to the Sensex over the past year and three years. The company also shows weak financial fundamentals, contributing to a perception of the stock as a strong sell.

As of 03-Dec, Vivo Bio Tech Ltd. is experiencing a decline in its stock price, currently at Rs 30.27, which reflects a change of -0.03 (-0.1%). The stock has been losing value for the past two days, with a total decline of -1.69% during this period. Additionally, it is trading close to its 52-week low, just 3.5% above Rs 29.21.<BR><BR>The stock's performance over various periods shows significant underperformance compared to the benchmark Sensex. Over the past year, Vivo Bio Tech has generated a return of -20.45%, while the Sensex has increased by 5.27%. This trend of underperformance extends over three years, where the stock has consistently lagged behind the benchmark, with a return of -13.51% compared to the Sensex's 35.37%.<BR><BR>Investor participation has also been declining, as evidenced by a 51.53% drop in delivery volume on December 2, compared to the five-day average. Furthermore, the stock is trading below its moving averages across multiple time frames, indicating a bearish trend.<BR><BR>Financially, the company faces challenges, including a weak long-term fundamental strength with a -0.84% compound annual growth rate (CAGR) in net sales over the last five years. The company's profitability is also low, with a return on equity of only 6.60% and a significant decline in profits of -45.2% over the past year. These factors contribute to a perception of the stock as a strong sell, further influencing its declining price.